April 4, 2019

Verseon Corporation (“Verseon” or the “Company”)

Additional Listing & Total Voting Rights

FREMONT, Calif.—Verseon, a technology-based pharmaceutical company, announces that application has been made for 171,974 new shares of common stock (“Common Shares”) of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units and grant of restricted stock award (the "Issuance").

Of the 171,974 Common Shares issued, 8,474 shares were issued to Dr. Hecht, and 150,000 of the Common Shares were issued to Dr. Kim, both non-executive Directors of the Company, in relation to the payment of their Director's fees. Dr. Kim’s shares are subject to a period of restriction of three years starting on November 5, 2018, the day Dr. Kim joined Verseon’s Board of Directors, and expiring with respect to 1/12 of the shares at the end of each three-month period.

Following the Issuance, Dr. Hecht will hold 98,517 Common Shares, representing 0.06% of the Company’s issued share capital and Dr. Kim will hold 150,000 Common Shares representing 0.09% of the Company’s issued share capital.

The 171,974 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on April 9, 2019 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 159,571,387 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,528,470. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information please contact:

Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
   
Arden Partners (NOMAD and Joint Broker)  
Ruari McGirr / Ciaran Walsh / Alex Penney +44 (0) 20 7614 5900
   
Cantor Fitzgerald Europe (Joint Broker)  
Phil Davies +44 (0) 20 7894 7000
   

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000
   

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen